Evidence map›Paper›PMID 29500915›Full record

ArticleProtein science : a publication of the Protein Society2018

A fusion-protein approach enabling mammalian cell production of tumor targeting protein domains for therapeutic development.

Jia Hu, Xiang Chen, Xuhua Zhang, Xiaopeng Yuan, Mingjuan Yang, Hui Dai, Wei Yang, Qinghua Zhou, Weihong Wen, Qirui Wang and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein science : a publication of the Protein Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Jia HuLung Cancer Research Center, West China Hospital, Sichuan University, Chengdu, China.
Xiang ChenAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Xuhua ZhangAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Xiaopeng YuanAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Mingjuan YangAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Hui DaiXinjiang Karamay Central Hospital, Karamay City, Xinjiang, China.
Wei YangAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Qinghua ZhouLung Cancer Research Center, West China Hospital, Sichuan University, Chengdu, China.
Weihong WenState Key Laboratory of Cancer Biology, Department of Immunology, Xijing Hospital, Fourth Military Medical University, China, Xi'an.
Qirui WangAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Weijun QinDepartment of Urology, Xijing Hospital, Fourth Military Medical University, China, Xi'an.
Aizhi ZhaoAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
University of Pennsylvania · USXijing Hospital · CNKaramay Central Hospital of Xinjiang · CNSichuan Cancer Hospital · CNSichuan University · CNSouthern Medical University · CN

Funding

Transformative personalized vascular disrupting cancer immunotherapyR01CA156695 · NCI · UNIVERSITY OF PENNSYLVANIA · PI COUKOS, GEORGE · 2010 to 2014
$3.0M
NCI NIH HHS R01 CA156695
6 · The paper itself

Abstract

A single chain Fv fragment (scFv) is a fusion of the variable regions of heavy (V

Indexed as

AnimalsCells, CulturedFrizzled ReceptorsHEK293 CellsHumansMiceNeoplasmsProtein DomainsReceptors, Cell SurfaceSingle-Chain AntibodiesFrizzled ReceptorsFZD10 protein, humanReceptors, Cell SurfaceSingle-Chain Antibodiestumor endothelial cell marker 7, mouseantibodiescancermammalian cellsrecombinant protein expressionscFvyeast library screening

Identifiers

PMID29500915
PMCPMC5916118
OpenAlexW2793393113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.